21 research outputs found
Pactes successoraux autorisés : de l’alchimie à la pratique
La conférence visait à faire un premier bilan après les trois premières années d'existence des pactes successoraux, en présentant les cas pratiques dans lesquels on peut envisager un pacte successoral
Targeting health subsidies through a non-price mechanism: A randomized controlled trial in Kenya
Free provision of preventive health products can dramatically increase access in low income countries. A cost concern about free provision is that some recipients may not use the product, wasting resources. Yet charging a price to screen out non-users may screen out poor people who need and would use the product. We report on a randomized controlled trial of a screening mechanism that combines free provision of chlorine solution for water treatment with a small non-monetary cost (voucher redemption). Relative to a non-voucher free distribution program, this mechanism reduces the quantity of chlorine procured by 60 percentage points, but reduces the share of households whose stored water tests positive for chlorine residual by only one percentage point, dramatically improving the tradeoff between over-inclusion and over-exclusion
p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance
International audienc
The relationship between renal function and plasma concentration of the cachectic factor zinc-alpha2-glycoprotein (ZAG) in adult patients with chronic kidney disease.
Zinc-α2-glycoprotein (ZAG), a potent cachectic factor, is increased in patients undergoing maintenance dialysis. However, there is no data for patients before initiation of renal replacement therapy. The purpose of the present study was to assess the relationship between plasma ZAG concentration and renal function in patients with a large range of glomerular filtration rate (GFR). Plasma ZAG concentration and its relationship to GFR were investigated in 71 patients with a chronic kidney disease (CKD) stage 1 to 5, 17 chronic hemodialysis (HD), 8 peritoneal dialysis (PD) and 18 non-CKD patients. Plasma ZAG concentration was 2.3-fold higher in CKD stage 5 patients and 3-fold higher in HD and PD patients compared to non-CKD controls (P<0.01). The hemodialysis session further increased plasma ZAG concentration (+39%, P<0.01). An inverse relationship was found between ZAG levels and plasma protein (rs = -0.284; P<0.01), albumin (rs = -0.282, P<0.05), hemoglobin (rs = -0.267, P<0.05) and HDL-cholesterol (rs = -0.264, P<0.05) and a positive correlation were seen with plasma urea (rs = 0.283; P<0.01). In multiple regression analyses, plasma urea and HDL-cholesterol were the only variables associated with plasma ZAG (r2 = 0.406, P<0.001). In CKD-5 patients, plasma accumulation of ZAG was not correlated with protein energy wasting. Further prospective studies are however needed to better elucidate the potential role of ZAG in end-stage renal disease
Plasma ZAG concentration increases during hemodialysis session.
<p>ZAG concentration was quantified by enzyme immunoassay before and after an hemodialysis session in ESRD patients (N = 8). ZAG concentrations were corrected for hemoconcentration as described in methods. Differences between pre and post dialysis concentrations were considered significant at the P<0.05 level (Wilcoxon test for paired samples). Abbreviation: HD, hemodialysis.</p
Plasma ZAG concentration is increased in end stage renal disease patients.
<p>ZAG concentration was quantified in plasma from non-CKD subjects (N = 18), chronic kidney disease (CKD stage 1 to 5, N = 71), hemodialysis (HD, N = 17) and peritoneal dialysis (PD, N = 8) patients by enzyme immunoassay. eGFR was estimated using CKD EPI formula as described in methods. Data are presented as median (interquartile range). Different letters indicate a significant difference at the P<0.05 level.</p